Can a new drug help people with aspirin allergy, asthma, and nasal polyps?

NCT ID NCT05575037

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This Phase 2 trial is testing dupilumab (Dupixent) in 17 people with aspirin-exacerbated respiratory disease (AERD), a condition that includes asthma, nasal polyps, and severe reactions to aspirin. The study aims to see if the drug can reduce markers of inflammation and improve sense of smell over 8 weeks. It is designed to understand how the drug works rather than to prove it is a cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dupilumab (Dupixent)
What this could lead to
If successful, this could point toward a treatment that improves smell and reduces nasal polyp burden in people with AERD.
What could go wrong
This is a very small, early-phase study (17 people) focused on understanding how the drug works, not on proving it is effective. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASPIRIN-EXACERBATED RESPIRATORY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.